Physician profile
Mark Faron
NPI 1356314041
$1,941.35
in general payments reported to CMS, 2019-2025
29 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $184 · 2022: $210 · 2023: $188 · 2024: $248 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $292.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $248.53 | 2019-2025 | |
| Pfizer INC. | $187.80 | 2019-2022 | |
| Abbvie INC. | $169.75 | 2022-2025 | |
| Novo Nordisk INC | $164.42 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $104.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.03 | 2019-2022 | |
| Allergan, INC. | $86.08 | 2020 | |
| Abbott Laboratories | $81.44 | 2019-2022 | |
| Astellas Pharma US INC | $61.07 | 2019-2024 | Veozah |
| Lilly USA, LLC | $49.12 | 2019 | |
| Dexcom, INC. | $46.16 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $44.82 | 2019 | |
| Shire North American Group INC | $34.24 | 2019 | |
| Edwards Lifesciences Corporation | $31.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.53 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.77 | 2019-2023 | Xifaxan |
| Radius Health, INC. | $23.03 | 2025 | Tymlos |
| Medtronic, INC. | $20.45 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $20.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.85 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.51 | 2023 | Linzess |
| Ge Healthcare | $18.21 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.82 | 2019 | |
| Sumitomo Pharma America, INC. | $15.72 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $13.28 | 2019 | |
| Insulet Corporation | $12.29 | 2019 | |
| Merck Sharp & Dohme LLC | $11.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Faron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.